Monitor the September 10, 2026 transfer deadline — if Polish regulatory approvals are not obtained by then, the $500K note becomes immediately due and payable, creating a cash liability for a company with a $7M market cap. The insider nature of the transaction (CEO is the lead buyer) warrants scrutiny of the Diagnosis S.A. stake's fair value.
Price Chart
Executive Summary
Biomerica entered into a Securities Purchase Agreement to sell its 6% stake (78,750 shares) in Diagnosis S.A. to buyers affiliated with CEO Zackary Irani for $500,000. The buyers paid via a secured promissory note that will be forgiven upon completion of the share transfer, which is subject to Polish regulatory approvals expected within 30 days. This is a related-party asset sale that converts a minority investment into cash for the company while creating a $500K secured debt obligation that converts to equity upon transfer.
Key Financial Metrics
Key Facts
- Biomerica sold 78,750 shares of Diagnosis S.A. (approx. 6% stake) for $500,000 to buyers including CEO Zackary Irani
- Buyers paid via a $500,000 secured promissory note bearing 8% interest, maturing in 12 months
- Note is forgivable upon completion of share transfer; transfer deadline is September 10, 2026
- Transfer requires Polish regulatory approvals expected within 30 days
- Diagnosis S.A. paid a $52,000 dividend to Biomerica in 2026, which was factored into the purchase price
- The buyers are insiders: CEO Zackary Irani ($300,000), AVR August LLC ($100,000), AVR September LLC ($100,000)
Financial Impact
Biomerica receives $500,000 cash for a non-core minority stake, representing a 6% position in a Polish diagnostics company. The company also received a $52,000 dividend from Diagnosis in 2026.
Risk Factors
- Transfer may fail to close by September 10, 2026, triggering immediate repayment of the $500K note
- Polish regulatory approval is a condition to closing and may be delayed or denied
- Related-party transaction with CEO raises governance questions about asset valuation
- The $500K represents ~7% of Biomerica's market cap, material for a micro-cap company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027290 |
| Document: form8-k.htm | 0001493152-26-027290 |
| Document: 0001493152-26-027290-index-headers.html | 0001493152-26-027290 |
| Document: 0001493152-26-027290-index.html | 0001493152-26-027290 |
| Document: 0001493152-26-027290.txt | 0001493152-26-027290 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | DEF 14A | $1.76 | awaiting T+20 | — | $1.79 (+1.70%) |
Oct 15, 2026 11d ago | 8-K | $1.85 | awaiting T+20 | — | $1.79 (−3.24%) |
Oct 8, 2026 19d ago | EFFECT | $1.89 | awaiting T+20 | — | $1.79 (−5.29%) |
Oct 8, 2026 19d ago | EFFECT | $1.89 | awaiting T+20 | — | $1.79 (−5.29%) |
Sep 25, 2026 4w ago | S-3 | $2.32 $1.68 | ▲ +27.59% | ▲ +26.11% | $1.79 (+22.84%) |
Sep 24, 2026 4w ago | S-3 | $2.32 $1.68 | ▲ +27.59% | ▲ +26.11% | $1.79 (+22.84%) |
Sep 1, 2026 8w ago | Press Release | $2.09 $2.26 | ▲ +8.13% | ▲ +7.82% | $1.79 (−14.35%) |
Aug 27, 2026 8w ago | Insider Cluster | $2.14 $2.39 | ▲ +11.68% | ▲ +12.16% | $1.79 (−16.36%) |
Aug 26, 2026 8w ago | 8-K | $2.10 $2.40 | ▼ −14.29% | ▼ −14.39% | $1.79 (+14.76%) |
Jun 4, 2026 20w ago | 8-K | $2.12 $1.73 | ▼ −18.40% | ▼ −20.26% | $1.79 (−15.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers